Export 95 results:
[ Author
Filters: First Letter Of Last Name is P [Clear All Filters]
“CORRELATION OF CLINICAL AND STRUCTURAL PROGRESSION WITH VISUAL ACUITY LOSS IN MACULAR TELANGIECTASIA TYPE 2: MacTel Project Report No. 6-The MacTel Research Group.”, Retina, vol. 38 Suppl 1, pp. S8-S13, 2018.
, “LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALS.”, Retina, vol. 39, no. 9, pp. 1802-1809, 2019.
, “Specifying Methodes for Mean VA Calculations [letter]”, J Cataract Refract Surg, vol. 36, pp. 184-185, 2010.
, “Specifying methods for mean VA calculations.”, J Cataract Refract Surg, vol. 36, no. 1, pp. 184-5; author reply 185, 2010.
, “Quality Issues in Clinical Research - Auditing for Improved Protocol Compliance”, in 20th Annual Conference of the Society for Clinical Data Management, Las Vegas, NV, 2014.
, “Rigid-compulsive behaviors are associated with mixed bowel symptoms in autism spectrum disorder.”, J Autism Dev Disord, vol. 44, no. 6, pp. 1425-32, 2014.
, “Phase 2A Dose and Route Study of a DNA Prime MVA Boost Vaccine Candidate”, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
, “Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.”, Vaccine, vol. 25, no. 11, pp. 2120-7, 2007.
, “Rigid-Compulsive Behaviors are Associated with Mixed Bowel Symptoms in Autism Spectrum Disorder”, J Autism Dev Disord, vol. 44, pp. 1425-1432, 2014.
, “Studies of a Prophylactic HIV-1 Vaccine Candidate Based on Modified Vaccinia Virus Ankara (MVA) with and without DNA Priming: Effects of Dosage and Route on Safety and Immunogenicity”, Vaccine, vol. 25, pp. 2120-2127, 2007.
, “Complementary and alternative medicine use in a large pediatric autism sample.”, Pediatrics, vol. 130 Suppl 2, pp. S77-82, 2012.
, “Complementary and Alternative Medicine Use in a Large Pediatric Autism Sample”, Pediatrics, vol. 130, pp. S77-S82, 2012.
, , “Changes in Seizure Frequency and Antiepileptic Therapy during Pregnancy.”, N Engl J Med, vol. 383, no. 26, pp. 2547-2556, 2020.
, “Differential effects of antiepileptic drugs on neonatal outcomes.”, Epilepsy Behav, vol. 24, no. 4, pp. 449-56, 2012.
, “Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.”, Science, vol. 373, no. 6561, pp. 1372-1377, 2021.
, “Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial.”, J Virol, vol. 87, no. 3, pp. 1708-19, 2013.
, “An empirical approach to determine a threshold for assessing overdispersion in Poisson and negative binomial models for count data.”, Commun Stat Simul Comput, vol. 47, no. 6, pp. 1722-1738, 2018.
, , “Fundus Autofluorescence Imaging in Macular Telangiectasia Type 2: MacTel Study Report Number 9.”, Am J Ophthalmol, vol. 228, pp. 27-34, 2021.
, “2009 Update from the Collaborative Islet Transplant Registry”, Paris France: , 2009.
, “Direct Comparison of an Inactivated Subvirion Influenza A Virus Subtype H5N1 Vaccine Administered by the Intradermal and Intramuscular Routes”, J Infect Dis, vol. 206, pp. 1069-1077, 2012.
, “Structural and Volumetric Brain MRI Findings in Mild Traumatic Brain Injury.”, AJNR Am J Neuroradiol, vol. 41, no. 1, pp. 92-99, 2020.
, “Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes.”, J Infect Dis, vol. 206, no. 7, pp. 1069-77, 2012.
, “Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.”, Biol Blood Marrow Transplant, vol. 24, no. 6, pp. 1274-1280, 2018.
,